Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
11 févr. 2019 07h00 HE
|
Apellis Pharmaceuticals, Inc.
New designation now includes all PNH patients WALTHAM Mass., and CRESTWOOD, Ky., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical...
Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
02 déc. 2018 12h01 HE
|
Apellis Pharmaceuticals, Inc.
Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of mean hemoglobin to 12.2 g/dL by day 85, an...
Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
13 nov. 2018 08h00 HE
|
Apellis Pharmaceuticals, Inc.
- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) - - Cash Position of $220.6 Million at Quarter-End - CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
07 nov. 2018 16h30 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
01 nov. 2018 10h50 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy
04 sept. 2018 07h30 HE
|
Apellis Pharmaceuticals, Inc.
PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™ CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 04, 2018 ...
Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
26 juin 2018 17h00 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
26 juin 2018 07h30 HE
|
Apellis Pharmaceuticals, Inc.
Severely anemic patients with PNH on treatment with Soliris™ can become transfusion-free with improved hemoglobin when switched to APL-2 monotherapy Treatment-naïve patients with PNH show clinically...
Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
16 avr. 2018 09h23 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
CORRECTION - Achillion Pharmaceuticals, Inc.
20 déc. 2017 12h12 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- In the news release issued earlier today by Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), please be advised the headline should read "Achillion...